211 related articles for article (PubMed ID: 37063928)
41. Impact of Double Expression of C-MYC/BCL2 Protein and Cell of Origin Subtypes on the Outcome among Patients with Diffuse Large B-Cell Lymphoma: a Single Asian Center Experience.
Teoh CS; Lee SY; Chiang SK; Chew TK; Goh AS
Asian Pac J Cancer Prev; 2018 May; 19(5):1229-1236. PubMed ID: 29801406
[TBL] [Abstract][Full Text] [Related]
42. Immunohistochemical subtyping of diffuse large B-cell lymphoma into germinal center B-cell and activated B-cell subtype, along with correlation of the subtypes with extranodal involvement, serum lactate dehydrogenase, and positron emission tomography scan-based response assessment to chemotherapy.
Tyagi A; Abrari A; Khurana A; Tyagi S
J Cancer Res Ther; 2022; 18(4):1129-1136. PubMed ID: 36149172
[TBL] [Abstract][Full Text] [Related]
43. Primary colorectal diffuse large B-cell lymphoma: A report of eighteen cases in a tertiary care center.
Vasconcelos FDC; Araujo ROC; Bernardo PS; Hancio T; de Moraes GN; Bigni RS; Valadão M; Pinto LW; Maia RC
Cancer Treat Res Commun; 2023; 36():100722. PubMed ID: 37331034
[TBL] [Abstract][Full Text] [Related]
44. Pretreatment lymphocyte-to-monocyte ratios predict AIDS-related diffuse large B-cell lymphoma overall survival.
Zeng J; Zhang X; Jia L; Wu Y; Tian Y; Zhang Y
J Med Virol; 2021 Jun; 93(6):3907-3914. PubMed ID: 33155687
[TBL] [Abstract][Full Text] [Related]
45. Clinical features, management, and prognosis of an international series of 161 patients with limited-stage diffuse large B-cell lymphoma of the bone (the IELSG-14 study).
Bruno Ventre M; Ferreri AJ; Gospodarowicz M; Govi S; Messina C; Porter D; Radford J; Heo DS; Park Y; Martinelli G; Taylor E; Lucraft H; Hong A; Scarfò L; Zucca E; Christie D;
Oncologist; 2014 Mar; 19(3):291-8. PubMed ID: 24567283
[TBL] [Abstract][Full Text] [Related]
46. [Clinical features and prognosis of 166 cases of MYC/BCL2 double-expression diffuse large B-cell lymphoma].
Tang SH; Tian L; Zhao W; Wang J; Ke XY
Zhonghua Xue Ye Xue Za Zhi; 2022 Sep; 43(9):771-777. PubMed ID: 36709172
[No Abstract] [Full Text] [Related]
47. Sites of extranodal involvement are prognostic in patients with diffuse large B-cell lymphoma in the rituximab era: an analysis of the Surveillance, Epidemiology and End Results database.
Castillo JJ; Winer ES; Olszewski AJ
Am J Hematol; 2014 Mar; 89(3):310-4. PubMed ID: 24273125
[TBL] [Abstract][Full Text] [Related]
48. Routine Imaging for Diffuse Large B-Cell Lymphoma in First Complete Remission Does Not Improve Post-Treatment Survival: A Danish-Swedish Population-Based Study.
El-Galaly TC; Jakobsen LH; Hutchings M; de Nully Brown P; Nilsson-Ehle H; Székely E; Mylam KJ; Hjalmar V; Johnsen HE; Bøgsted M; Jerkeman M
J Clin Oncol; 2015 Dec; 33(34):3993-8. PubMed ID: 26438115
[TBL] [Abstract][Full Text] [Related]
49. Ocular adnexal diffuse large B-cell lymphoma: a multicenter international study.
Munch-Petersen HD; Rasmussen PK; Coupland SE; Esmaeli B; Finger PT; Graue GF; Grossniklaus HE; Honavar SG; Khong JJ; McKelvie PA; Mulay K; Prause JU; Ralfkiaer E; Sjö LD; Sniegowski MC; Vemuganti GK; Heegaard S
JAMA Ophthalmol; 2015 Feb; 133(2):165-73. PubMed ID: 25393033
[TBL] [Abstract][Full Text] [Related]
50. CD5 positivity is an independent adverse prognostic factor in elderly patients with diffuse large B cell lymphoma.
Chuang WY; Chang H; Shih LY; Wang PN; Chang YS; Lin TL; Hung YS; Yeh CJ; Ueng SH; Tang TC; Kuo MC; Dunn P; Wu JH; Kao HW; Ou CW; Wan YL; Hsueh C
Virchows Arch; 2015 Nov; 467(5):571-82. PubMed ID: 26369546
[TBL] [Abstract][Full Text] [Related]
51. Prognostic value of metabolic tumour volume on baseline
Shagera QA; Cheon GJ; Koh Y; Yoo MY; Kang KW; Lee DS; Kim EE; Yoon SS; Chung JK
Eur J Nucl Med Mol Imaging; 2019 Jul; 46(7):1417-1427. PubMed ID: 30941463
[TBL] [Abstract][Full Text] [Related]
52. BCL2 Expression in First-Line Diffuse Large B-Cell Lymphoma Identifies a Patient Population With Poor Prognosis.
Punnoose E; Peale FV; Szafer-Glusman E; Lei G; Bourgon R; Do AD; Kim E; Zhang L; Farinha P; Gascoyne RD; Munoz FJ; Martelli M; Mottok A; Salles GA; Sehn LH; Seymour JF; Trnĕný M; Oestergaard MZ; Mundt KE; Vitolo U
Clin Lymphoma Myeloma Leuk; 2021 Apr; 21(4):267-278.e10. PubMed ID: 33303421
[TBL] [Abstract][Full Text] [Related]
53. The role of tumor histogenesis, FDG-PET, and short-course EPOCH with dose-dense rituximab (SC-EPOCH-RR) in HIV-associated diffuse large B-cell lymphoma.
Dunleavy K; Little RF; Pittaluga S; Grant N; Wayne AS; Carrasquillo JA; Steinberg SM; Yarchoan R; Jaffe ES; Wilson WH
Blood; 2010 Apr; 115(15):3017-24. PubMed ID: 20130244
[TBL] [Abstract][Full Text] [Related]
54. Impact of concordant and discordant bone marrow involvement on outcome in diffuse large B-cell lymphoma treated with R-CHOP.
Sehn LH; Scott DW; Chhanabhai M; Berry B; Ruskova A; Berkahn L; Connors JM; Gascoyne RD
J Clin Oncol; 2011 Apr; 29(11):1452-7. PubMed ID: 21383296
[TBL] [Abstract][Full Text] [Related]
55. A promising prognostic model for predicting survival of patients with HIV-related diffuse large B-cell lymphoma in the cART era.
Chen J; Wu Y; Kang Z; Qin S; Ruan G; Zhao H; Tao X; Xie Z; Peng J
Cancer Med; 2023 Jun; 12(11):12470-12481. PubMed ID: 37081761
[TBL] [Abstract][Full Text] [Related]
56. TRPM4 expression is associated with activated B cell subtype and poor survival in diffuse large B cell lymphoma.
Loo SK; Ch'ng ES; Md Salleh MS; Banham AH; Pedersen LM; Møller MB; Green TM; Wong KK
Histopathology; 2017 Jul; 71(1):98-111. PubMed ID: 28248435
[TBL] [Abstract][Full Text] [Related]
57. [Analysis of survival and prognosis in 409 newly diagnosed patients with diffuse large B-cell lymphoma].
Wen J; Zhou J; Liu Z; Liu T; Xu C
Zhonghua Xue Ye Xue Za Zhi; 2014 Apr; 35(4):318-24. PubMed ID: 24759020
[TBL] [Abstract][Full Text] [Related]
58. Survival of AIDS-related diffuse large B-cell lymphoma, Burkitt lymphoma, and plasmablastic lymphoma in the German HIV Lymphoma Cohort.
Schommers P; Hentrich M; Hoffmann C; Gillor D; Zoufaly A; Jensen B; Bogner JR; Thoden J; Wasmuth JC; Wolf T; Oette M; Müller M; Esser S; Vehreschild JJ; Fätkenheuer G; Wyen C
Br J Haematol; 2015 Mar; 168(6):806-10. PubMed ID: 25403997
[TBL] [Abstract][Full Text] [Related]
59. Clinical characteristics and outcomes of extranodal stage I diffuse large B-cell lymphoma in the rituximab era.
Bobillo S; Joffe E; Lavery JA; Sermer D; Ghione P; Noy A; Caron PC; Hamilton A; Hamlin PA; Horwitz SM; Kumar A; Matasar MJ; Moskowitz A; Owens CN; Palomba ML; Batlevi CL; Straus D; von Keudell G; Zelenetz AD; Yahalom J; Dogan A; Seshan VE; Younes A
Blood; 2021 Jan; 137(1):39-48. PubMed ID: 32730585
[TBL] [Abstract][Full Text] [Related]
60. [Clinicpathological features and survival of patients with AIDS related non-Hodgkin's lymphoma].
Sun KY; Gui XE; Deng D; Xiong Y; Deng LP; Gao SC; Zhang YX
Zhonghua Xue Ye Xue Za Zhi; 2017 Feb; 38(2):97-101. PubMed ID: 28279031
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
